Emergence of Daptomycin-Resistant VRE: Experience of a Single Institution
Infection Control and Hospital Epidemiology2011Vol. 32(4), pp. 391–394
Citations Over TimeTop 10% of 2011 papers
Abstract
Recent surveillance from US hospitals shows that more than 99.5% of vancomycin-resistant enterococci (VRE) isolates remain susceptible to daptomycin. This report describes emergence of daptomycin-resistant VRE at a major cancer center. The percentage of patients with daptomycin-resistant VRE bacteremia increased from 3.4% in 2007 to 15.2% in 2009 ([Formula: see text]). Without susceptibility data, empiric daptomycin therapy for VRE infections should be used with caution.
Related Papers
- → Addition of Ceftaroline to Daptomycin after Emergence of Daptomycin-Nonsusceptible Staphylococcus aureus during Therapy Improves Antibacterial Activity(2012)111 cited
- → Establishing the Structure–Activity Relationship of Daptomycin(2020)40 cited
- → The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA(2014)42 cited
- → Defining the Active Fraction of Daptomycin against Methicillin-Resistant Staphylococcus aureus (MRSA) Using a Pharmacokinetic and Pharmacodynamic Approach(2016)7 cited
- Susquehanna Chorale Spring Concert "Roots and Wings"(2017)